REFERENCES
1. van Zelm MC, McKenzie CI, Varese N, Rolland JM, O’Hehir RE. Recent developments and highlights in immune monitoring of allergen immunotherapy. Allergy. 2019;74(12):2342-2354.
2. Valenta R, Karaulov A, Niederberger V, et al. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? The Journal of Allergy and Clinical Immunology: In Practice.2018;6(6):1845-1855.e1842.
3. Carnés J, Iraola V, Cho SH, Esch RE. Mite allergen extracts and clinical practice. Annals of Allergy, Asthma & Immunology.2017;118(3):249-256.
4. Codina R, Lockey RF. Pollen used to produce allergen extracts.Annals of Allergy, Asthma & Immunology. 2017;118(2):148-153.
5. Frick M, Fischer J, Helbling A, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. Journal of Allergy and Clinical Immunology.2016;138(6):1663-1671.e1669.
6. Rolland JM, Varese NP, Abramovitch JB, et al. Effect of Heat Processing on IgE Reactivity and Cross-Reactivity of Tropomyosin and Other Allergens of Asia-Pacific Mollusc Species: Identification of Novel Sydney Rock Oyster Tropomyosin Sac g 1. Molecular Nutrition & Food Research. 2018;62(14):1800148.
7. Vieths S, Hoffmann A, Holzhauser T, Muller U, Reindl J, Haustein D. Factors influencing the quality of food extracts for in vitro and in vivo diagnosis. Allergy. 1998;53(46 Suppl):65-71.
8. Uyttebroek AP, Sabato V, Faber MA, et al. Basophil activation tests: time for a reconsideration. Expert Review of Clinical Immunology.2014;10(10):1325-1335.
9. MacGlashan DW. Basophil activation testing. Journal of Allergy and Clinical Immunology. 2013;132(4):777-787.
10. Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393-1405.
11. Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis in Hymenoptera venom allergy. Current Opinion in Allergy and Clinical Immunology. 2019;19(6).
12. Luengo O, Cardona V. Component resolved diagnosis: when should it be used? Clinical and Translational Allergy. 2014;4(1):28.
13. Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. Journal of Allergy and Clinical Immunology. 2014;134(1):75-81.e72.
14. Huang HJ, Resch-Marat Y, Rodriguez-Dominguez A, et al. Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. J Allergy Clin Immunol. 2018;142(5):1656-1659 e1659.
15. Huang Y, Wang C, Lin X, et al. Association between component-resolved diagnosis of house dust mite and efficacy of allergen immunotherapy in allergic rhinitis patients. Clin Transl Allergy.2019;9:64.
16. Dang TD, Tang M, Choo S, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol.2012;129(4):1056-1063.
17. Lieberman JA, Glaumann S, Batelson S, Borres MP, Sampson HA, Nilsson C. The utility of peanut components in the diagnosis of IgE-mediated peanut allergy among distinct populations. J Allergy Clin Immunol Pract. 2013;1(1):75-82.
18. Treudler R, Simon JC. Overview of component resolved diagnostics.Curr Allergy Asthma Rep. 2013;13(1):110-117.
19. Köhler J, Blank S, Müller S, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy.Journal of Allergy and Clinical Immunology.2014;133(5):1383-1389.e1386.
20. Matthiesen F, Løwenstein H. Group V allergens in grass pollens. II. Investigation of group V allergens in pollens from 10 grasses.Clinical & Experimental Allergy. 1991;21(3):309-320.
21. Ong EK, Knox RB, Singh MB. Mapping of the antigenic and allergenic epitopes of Lol p VB using gene fragmentation. Molecular Immunology. 1995;32(4):295-302.
22. Tamborini E, Faccini S, Lidholm J, et al. Biochemical and Immunological Characterization of Recombinant Allergen Lol p 1.European Journal of Biochemistry. 1997;249(3):886-894.
23. Niederberger V, Laffer S, Froschl R, et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol. 1998;101(2 Pt 1):258-264.
24. Hew M, Lee J, Varese N, et al. Epidemic thunderstorm asthma susceptibility from sensitization to ryegrass (Lolium perenne) pollen and major allergen Lol p 5. Allergy. 2020.
25. Knox RB. Grass pollen, thunderstorms and asthma. Clin Exp Allergy. 1993;23(5):354-359.
26. O’Hehir RE, Varese NP, Deckert K, et al. Epidemic Thunderstorm Asthma Protection with Five-Grass Pollen Tablet Sublingual Immunotherapy: A Clinical Trial. Am J Respir Crit Care Med.2018;198(1):126-128.
27. Müller U, Schmid-Grendelmeier P, Hausmann O, Helbling A. IgE to recombinant allergens Api m 1, Ves v 1, and Ves v 5 distinguish double sensitization from crossreaction in venom allergy. Allergy.2012;67(8):1069-1073.
28. Müller UR, Johansen N, Petersen AB, Fromberg-Nielsen J, Haeberli G. Hymenoptera venom allergy: analysis of double positivity to honey bee and Vespula venom by estimation of IgE antibodies to species-specific major allergens Api m1 and Ves v5. Allergy. 2009;64(4):543-548.
29. Jakob T, Müller U, Helbling A, Spillner E. Component resolved diagnostics for hymenoptera venom allergy. Current opinion in allergy and clinical immunology. 2017;17(5):363-372.
30. Whitrow MJ, Moore VM, Rumbold AR, Davies MJ. Effect of supplemental folic acid in pregnancy on childhood asthma: a prospective birth cohort study. American journal of epidemiology. 2009;170(12):1486-1493.
31. Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy. 2020;75(5):1121-1132.
32. Chan SK, Pomes A, Hilger C, et al. Keeping Allergen Names Clear and Defined. Front Immunol. 2019;10:2600.
33. Pomes A, Davies JM, Gadermaier G, et al. WHO/IUIS Allergen Nomenclature: Providing a common language. Mol Immunol.2018;100:3-13.
34. Förster E, Dudlerb T, Gmachl M, Aberer W, Urbanek R, Suter M. Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy.Journal of Allergy and Clinical Immunology. 1995;95(6):1229-1235.
35. Grobe K, Pöppelmann M, Becker W-M, Petersen A. Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases. European Journal of Biochemistry. 2002;269(8):2083-2092.
36. Apostolou E, Deckert K, Puy R, et al. Anaphylaxis to Gelofusine confirmed by in vitro basophil activation test: a case series.Anaesthesia. 2006;61(3):264-268.
37. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
38. Edwards ESJ, Bosco JJ, Aui PM, et al. Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells. Front Immunol.2019;10:2593.
39. Altmann F. The Role of Protein Glycosylation in Allergy.International Archives of Allergy and Immunology.2007;142(2):99-115.
40. Halim A, Carlsson MC, Madsen CB, et al. Glycoproteomic analysis of seven major allergenic proteins reveals novel post-translational modifications. Mol Cell Proteomics. 2015;14(1):191-204.
41. Strasser R. Plant protein glycosylation. Glycobiology.2016;26(9):926-939.
42. Rendj D, Wilson IBH, Paschinger K. The Glycosylation Capacity of Insect Cells. 2008.
43. Shi X, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets. 2007;8(10):1116-1125.
44. Blank S, Michel Y, Seismann H, et al. Evaluation of different glycoforms of honeybee venom major allergen phospholipase A2 (Api m 1) produced in insect cells. Protein Pept Lett. 2011;18(4):415-422.
45. Koren A, Lunder M, Molek P, et al. Fluorescent labeling of major honeybee allergens Api m 1 and Api m 2 with quantum dots and the development of a multiplex basophil activation test. Allergy.2020;75(7):1753-1756.
46. Chirumbolo S, Vella A, Ortolani R, et al. Differential response of human basophil activation markers: a multi-parameter flow cytometry approach. Clin Mol Allergy. 2008;6:12.
47. Prussin C, Metcalfe DD. 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006;117(2 Suppl Mini-Primer):S450-456.
48. Knol EF. Requirements for effective IgE cross-linking on mast cells and basophils. Molecular Nutrition & Food Research.2006;50(7):620-624.
49. Mukai K, Chinthrajah RS, Nadeau KC, Tsai M, Gaudenzio N, Galli SJ. A new fluorescent-avidin–based method for quantifying basophil activation in whole blood. Journal of Allergy and Clinical Immunology.2017;140(4):1202-1206.e1203.
50. Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A, Aberer W. The basophil activation test in the diagnosis of allergy: technical issues and critical factors. Allergy.2009;64(9):1319-1326.
51. Wagner N, Rudert M. Sensitivity and specificity of standardised allergen extracts in skin prick test for diagnoses of IgE-mediated respiratory allergies. Clinical and Translational Allergy.2019;9(1):8.